Physician profile
Christopher J Lambring
NPI 1043449440
$1,843.49
in general payments reported to CMS, 2019-2025
24 companies · $538 in 2025
The $538 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $70.91 · 2021: $160 · 2022: $253 · 2023: $296 · 2024: $341 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $365.87 | 2019-2025 | Acuvue |
| Regeneron Healthcare Solutions, INC. | $258.73 | 2020-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $161.73 | 2023-2025 | Precision7, Rocklatan, Clareon |
| Abbvie INC. | $152.21 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $91.86 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $84.93 | 2022-2025 | Infuse, Vyzulta |
| Allergan, INC. | $83.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $60.23 | 2020-2021 | |
| Astellas Pharma US INC | $59.45 | 2023-2025 | Izervay |
| Harrow Eye, LLC | $55.84 | 2024-2025 | Triesence, Iheezo |
| Apellis Pharmaceuticals, INC. | $55.63 | 2023-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $52.65 | 2019-2021 | |
| Oyster Point Pharma, INC. | $52.20 | 2022-2023 | Tyrvaya |
| Shire North American Group INC | $44.31 | 2019 | |
| Biotissue Holdings INC. | $34.52 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.37 | 2025 | Vabysmo |
| Sight Sciences, INC. | $33.30 | 2022-2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $33.30 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $27.54 | 2024 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.42 | 2019 | |
| Glaukos Corporation | $24.07 | 2023 | |
| Mallinckrodt Hospital Products INC. | $23.95 | 2023 | Acthar |
| Horizon Therapeutics Plc | $13.73 | 2022 | |
| Rxsight INC | $13.32 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lambring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.